Co-treatment of JQ1 and EZH2 inhibitor (DZNep) cooperatively inhibited MYC activation, thereby significantly restoring miR-26a expression and synergistically suppressing lymphoma growth and clonogenicity in DLBCL, BL, and MCL cells [65]. Here, MYC is linked to lymphoma.